High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-09-16

AUTHORS

Janice P Dutcher, Douglas J Schwartzentruber, Howard L Kaufman, Sanjiv S Agarwala, Ahmad A Tarhini, James N Lowder, Michael B Atkins

ABSTRACT

Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. The majority of complete responders with metastatic renal cell carcinoma (mRCC) and metastatic melanoma (mM) could probably be classified as "cures". Recent publications have suggested improved efficacy, perhaps due to improved patient selection based on a better understanding of clinical features predicting outcomes. Guidelines for clinical management were established from experience at the National Cancer Institute (NCI) and an affiliation of institutions known as the Cytokine Working Group (CWG), who were among the first to utilize HD IL-2 treatment outside of the NCI. As new centers have opened, further management variations have emerged based upon center-specific experience, to optimize administration of IL-2 and provide high quality care for patients at each individual site. Twenty years of evolution in differing environments has led to a plethora of clinical experience and effective management approaches. The goal of this review is to summarize the spectrum of HD IL-2 treatment approaches, describing various effective strategies that incorporate newer adjunctive treatments for managing the side effects of IL-2 in patients with mRCC and mM. The goal for IL-2 therapy is typically to administer the maximum number of doses of IL-2 without putting the patient at unacceptable risk for severe, irreversible toxicity. This review is based upon a consensus meeting and includes guidelines on pre-treatment screening, criteria for administration and withholding doses, and defines consensus criteria for safe administration and toxicity management. The somewhat heterogeneous best practices of 2014 will be compared and contrasted with the guidelines provided in 2001 and the package inserts from 1992 and 1998. More... »

PAGES

26

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-014-0026-0

DOI

http://dx.doi.org/10.1186/s40425-014-0026-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1026833788

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31546315


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Associate Director, Cancer Research Foundation, Chappaqua, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.478570.9", 
          "name": [
            "Associate Director, Cancer Research Foundation, Chappaqua, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dutcher", 
        "givenName": "Janice P", 
        "id": "sg:person.0760406720.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760406720.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Associate Director of Clinical Operations, Professor of Surgery, IU Simon Cancer Center, 550 N University Blvd, 46202, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.257413.6", 
          "name": [
            "Associate Director of Clinical Operations, Professor of Surgery, IU Simon Cancer Center, 550 N University Blvd, 46202, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartzentruber", 
        "givenName": "Douglas J", 
        "id": "sg:person.013051102007.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013051102007.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chief Surgical Officer and Associate Director for Clinical Science, Professor of Surgery, Rutgers Cancer Center Institute of New Jersey, 195 Little Albany Street, Room 2007, 08901, New Brunswick, NJ, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Chief Surgical Officer and Associate Director for Clinical Science, Professor of Surgery, Rutgers Cancer Center Institute of New Jersey, 195 Little Albany Street, Room 2007, 08901, New Brunswick, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaufman", 
        "givenName": "Howard L", 
        "id": "sg:person.01333264012.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333264012.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chief of Medical Oncology and Professor of Medicine, St. Luke's Cancer Center, 18015, Bethlehem, PA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Chief of Medical Oncology and Professor of Medicine, St. Luke's Cancer Center, 18015, Bethlehem, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agarwala", 
        "givenName": "Sanjiv S", 
        "id": "sg:person.01160762514.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160762514.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Associate Professor of Medicine and Translational Science, University of Pittsburgh Cancer Institute, Suite 555, 5150 Centre Ave, 15232, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.478063.e", 
          "name": [
            "Associate Professor of Medicine and Translational Science, University of Pittsburgh Cancer Institute, Suite 555, 5150 Centre Ave, 15232, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tarhini", 
        "givenName": "Ahmad A", 
        "id": "sg:person.0743573635.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743573635.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Senior Medical Director, Prometheus Laboratories Inc, 9410 Carroll Park Drive, 92121, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.437284.e", 
          "name": [
            "Senior Medical Director, Prometheus Laboratories Inc, 9410 Carroll Park Drive, 92121, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lowder", 
        "givenName": "James N", 
        "id": "sg:person.01067561552.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067561552.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Deputy Director, Professor of Medicine, Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Rd NW, NRB-E501, 20057, Washington, DC, USA", 
          "id": "http://www.grid.ac/institutes/grid.213910.8", 
          "name": [
            "Deputy Director, Professor of Medicine, Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Rd NW, NRB-E501, 20057, Washington, DC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Atkins", 
        "givenName": "Michael B", 
        "id": "sg:person.010266621557.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010266621557.13"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/ajg.2008.138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028232194", 
          "https://doi.org/10.1038/ajg.2008.138"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1385/mo:18:3:209", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052059090", 
          "https://doi.org/10.1385/mo:18:3:209"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00916947", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019136705", 
          "https://doi.org/10.1007/bf00916947"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-09-16", 
    "datePublishedReg": "2014-09-16", 
    "description": "Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. The majority of complete responders with metastatic renal cell carcinoma (mRCC) and metastatic melanoma (mM) could probably be classified as \"cures\". Recent publications have suggested improved efficacy, perhaps due to improved patient selection based on a better understanding of clinical features predicting outcomes. Guidelines for clinical management were established from experience at the National Cancer Institute (NCI) and an affiliation of institutions known as the Cytokine Working Group (CWG), who were among the first to utilize HD IL-2 treatment outside of the NCI. As new centers have opened, further management variations have emerged based upon center-specific experience, to optimize administration of IL-2 and provide high quality care for patients at each individual site. Twenty years of evolution in differing environments has led to a plethora of clinical experience and effective management approaches. The goal of this review is to summarize the spectrum of HD IL-2 treatment approaches, describing various effective strategies that incorporate newer adjunctive treatments for managing the side effects of IL-2 in patients with mRCC and mM. The goal for IL-2 therapy is typically to administer the maximum number of doses of IL-2 without putting the patient at unacceptable risk for severe, irreversible toxicity. This review is based upon a consensus meeting and includes guidelines on pre-treatment screening, criteria for administration and withholding doses, and defines consensus criteria for safe administration and toxicity management. The somewhat heterogeneous best practices of 2014 will be compared and contrasted with the guidelines provided in 2001 and the package inserts from 1992 and 1998.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s40425-014-0026-0", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "publisher": "BMJ", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "National Cancer Institute", 
      "Cytokine Working Group", 
      "interleukin-2", 
      "complete response", 
      "stage IV solid tumors", 
      "HD IL-2 treatment", 
      "center-specific experience", 
      "new adjunctive treatment", 
      "IL-2 therapy", 
      "IL-2 treatment", 
      "renal cell carcinoma", 
      "pre-treatment screening", 
      "high-quality care", 
      "complete responders", 
      "further therapy", 
      "adjunctive treatment", 
      "clinical features", 
      "patient selection", 
      "cell carcinoma", 
      "metastatic melanoma", 
      "clinical management", 
      "toxicity management", 
      "safe administration", 
      "consensus meeting", 
      "Cancer Institute", 
      "side effects", 
      "clinical experience", 
      "treatment approaches", 
      "solid tumors", 
      "consensus criteria", 
      "quality care", 
      "irreversible toxicity", 
      "improved efficacy", 
      "patients", 
      "administration", 
      "therapy", 
      "treatment", 
      "doses", 
      "effective management approach", 
      "guidelines", 
      "management variations", 
      "Working Group", 
      "unacceptable risk", 
      "review", 
      "carcinoma", 
      "effective strategy", 
      "tumors", 
      "melanoma", 
      "responders", 
      "recent publications", 
      "care", 
      "efficacy", 
      "cure", 
      "adults", 
      "outcomes", 
      "management", 
      "risk", 
      "criteria", 
      "toxicity", 
      "experience", 
      "screening", 
      "years of evolution", 
      "better understanding", 
      "group", 
      "majority", 
      "years", 
      "best practices", 
      "practice", 
      "response", 
      "management approach", 
      "consensus", 
      "center", 
      "Institute", 
      "effect", 
      "new centers", 
      "meeting", 
      "goal", 
      "publications", 
      "institutions", 
      "strategies", 
      "sites", 
      "number", 
      "maximum number", 
      "decades", 
      "plethora", 
      "features", 
      "understanding", 
      "approach", 
      "individual sites", 
      "selection", 
      "variation", 
      "affiliation", 
      "package", 
      "environment", 
      "spectra", 
      "management practices", 
      "evolution", 
      "best management practices"
    ], 
    "name": "High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014", 
    "pagination": "26", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1026833788"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-014-0026-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31546315"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-014-0026-0", 
      "https://app.dimensions.ai/details/publication/pub.1026833788"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_637.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s40425-014-0026-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0026-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0026-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0026-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0026-0'


 

This table displays all metadata directly associated to this object as RDF triples.

230 TRIPLES      21 PREDICATES      127 URIs      116 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-014-0026-0 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N9c681e7eb7db4534ba2d3cdf5cc183e2
4 schema:citation sg:pub.10.1007/bf00916947
5 sg:pub.10.1038/ajg.2008.138
6 sg:pub.10.1385/mo:18:3:209
7 schema:datePublished 2014-09-16
8 schema:datePublishedReg 2014-09-16
9 schema:description Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. The majority of complete responders with metastatic renal cell carcinoma (mRCC) and metastatic melanoma (mM) could probably be classified as "cures". Recent publications have suggested improved efficacy, perhaps due to improved patient selection based on a better understanding of clinical features predicting outcomes. Guidelines for clinical management were established from experience at the National Cancer Institute (NCI) and an affiliation of institutions known as the Cytokine Working Group (CWG), who were among the first to utilize HD IL-2 treatment outside of the NCI. As new centers have opened, further management variations have emerged based upon center-specific experience, to optimize administration of IL-2 and provide high quality care for patients at each individual site. Twenty years of evolution in differing environments has led to a plethora of clinical experience and effective management approaches. The goal of this review is to summarize the spectrum of HD IL-2 treatment approaches, describing various effective strategies that incorporate newer adjunctive treatments for managing the side effects of IL-2 in patients with mRCC and mM. The goal for IL-2 therapy is typically to administer the maximum number of doses of IL-2 without putting the patient at unacceptable risk for severe, irreversible toxicity. This review is based upon a consensus meeting and includes guidelines on pre-treatment screening, criteria for administration and withholding doses, and defines consensus criteria for safe administration and toxicity management. The somewhat heterogeneous best practices of 2014 will be compared and contrasted with the guidelines provided in 2001 and the package inserts from 1992 and 1998.
10 schema:genre article
11 schema:isAccessibleForFree true
12 schema:isPartOf N7160167c339543ed9272cd9d45bab5cc
13 N78269ee908774ac7bd3553cb02be57c6
14 sg:journal.1049249
15 schema:keywords Cancer Institute
16 Cytokine Working Group
17 HD IL-2 treatment
18 IL-2 therapy
19 IL-2 treatment
20 Institute
21 National Cancer Institute
22 Working Group
23 adjunctive treatment
24 administration
25 adults
26 affiliation
27 approach
28 best management practices
29 best practices
30 better understanding
31 carcinoma
32 care
33 cell carcinoma
34 center
35 center-specific experience
36 clinical experience
37 clinical features
38 clinical management
39 complete responders
40 complete response
41 consensus
42 consensus criteria
43 consensus meeting
44 criteria
45 cure
46 decades
47 doses
48 effect
49 effective management approach
50 effective strategy
51 efficacy
52 environment
53 evolution
54 experience
55 features
56 further therapy
57 goal
58 group
59 guidelines
60 high-quality care
61 improved efficacy
62 individual sites
63 institutions
64 interleukin-2
65 irreversible toxicity
66 majority
67 management
68 management approach
69 management practices
70 management variations
71 maximum number
72 meeting
73 melanoma
74 metastatic melanoma
75 metastatic renal cell carcinoma
76 new adjunctive treatment
77 new centers
78 number
79 outcomes
80 package
81 patient selection
82 patients
83 plethora
84 practice
85 pre-treatment screening
86 publications
87 quality care
88 recent publications
89 renal cell carcinoma
90 responders
91 response
92 review
93 risk
94 safe administration
95 screening
96 selection
97 side effects
98 sites
99 solid tumors
100 spectra
101 stage IV solid tumors
102 strategies
103 therapy
104 toxicity
105 toxicity management
106 treatment
107 treatment approaches
108 tumors
109 unacceptable risk
110 understanding
111 variation
112 years
113 years of evolution
114 schema:name High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
115 schema:pagination 26
116 schema:productId Nd9c0a447e87f4c6898d69b6cdf8f78c0
117 Ne68713ee20aa4a3a8674a17bf2596960
118 Nf5df1fdb8c8345c3b5eae91fcce8207e
119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026833788
120 https://doi.org/10.1186/s40425-014-0026-0
121 schema:sdDatePublished 2022-09-02T15:57
122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
123 schema:sdPublisher Nc487cef6e6e048af98bada2b1758b264
124 schema:url https://doi.org/10.1186/s40425-014-0026-0
125 sgo:license sg:explorer/license/
126 sgo:sdDataset articles
127 rdf:type schema:ScholarlyArticle
128 N1decac09ef1d4235bae26faa9ee05bca rdf:first sg:person.010266621557.13
129 rdf:rest rdf:nil
130 N4281888b4d2d4ec1ab17678c51dee68a rdf:first sg:person.01067561552.17
131 rdf:rest N1decac09ef1d4235bae26faa9ee05bca
132 N5ef5609408d1483ba07a454ee7db4df5 rdf:first sg:person.01160762514.70
133 rdf:rest N9e4e9783f7874671a7c3e231f8526642
134 N6254fb27c40a4092a1fed2232db4fbf9 rdf:first sg:person.013051102007.09
135 rdf:rest Neefb6853c64441b9a06c01c2744c44a3
136 N7160167c339543ed9272cd9d45bab5cc schema:issueNumber 1
137 rdf:type schema:PublicationIssue
138 N78269ee908774ac7bd3553cb02be57c6 schema:volumeNumber 2
139 rdf:type schema:PublicationVolume
140 N9c681e7eb7db4534ba2d3cdf5cc183e2 rdf:first sg:person.0760406720.36
141 rdf:rest N6254fb27c40a4092a1fed2232db4fbf9
142 N9e4e9783f7874671a7c3e231f8526642 rdf:first sg:person.0743573635.60
143 rdf:rest N4281888b4d2d4ec1ab17678c51dee68a
144 Nc487cef6e6e048af98bada2b1758b264 schema:name Springer Nature - SN SciGraph project
145 rdf:type schema:Organization
146 Nd9c0a447e87f4c6898d69b6cdf8f78c0 schema:name dimensions_id
147 schema:value pub.1026833788
148 rdf:type schema:PropertyValue
149 Ne68713ee20aa4a3a8674a17bf2596960 schema:name doi
150 schema:value 10.1186/s40425-014-0026-0
151 rdf:type schema:PropertyValue
152 Neefb6853c64441b9a06c01c2744c44a3 rdf:first sg:person.01333264012.85
153 rdf:rest N5ef5609408d1483ba07a454ee7db4df5
154 Nf5df1fdb8c8345c3b5eae91fcce8207e schema:name pubmed_id
155 schema:value 31546315
156 rdf:type schema:PropertyValue
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
161 schema:name Oncology and Carcinogenesis
162 rdf:type schema:DefinedTerm
163 sg:journal.1049249 schema:issn 2051-1426
164 schema:name Journal for ImmunoTherapy of Cancer
165 schema:publisher BMJ
166 rdf:type schema:Periodical
167 sg:person.010266621557.13 schema:affiliation grid-institutes:grid.213910.8
168 schema:familyName Atkins
169 schema:givenName Michael B
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010266621557.13
171 rdf:type schema:Person
172 sg:person.01067561552.17 schema:affiliation grid-institutes:grid.437284.e
173 schema:familyName Lowder
174 schema:givenName James N
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067561552.17
176 rdf:type schema:Person
177 sg:person.01160762514.70 schema:affiliation grid-institutes:None
178 schema:familyName Agarwala
179 schema:givenName Sanjiv S
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160762514.70
181 rdf:type schema:Person
182 sg:person.013051102007.09 schema:affiliation grid-institutes:grid.257413.6
183 schema:familyName Schwartzentruber
184 schema:givenName Douglas J
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013051102007.09
186 rdf:type schema:Person
187 sg:person.01333264012.85 schema:affiliation grid-institutes:None
188 schema:familyName Kaufman
189 schema:givenName Howard L
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333264012.85
191 rdf:type schema:Person
192 sg:person.0743573635.60 schema:affiliation grid-institutes:grid.478063.e
193 schema:familyName Tarhini
194 schema:givenName Ahmad A
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743573635.60
196 rdf:type schema:Person
197 sg:person.0760406720.36 schema:affiliation grid-institutes:grid.478570.9
198 schema:familyName Dutcher
199 schema:givenName Janice P
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760406720.36
201 rdf:type schema:Person
202 sg:pub.10.1007/bf00916947 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019136705
203 https://doi.org/10.1007/bf00916947
204 rdf:type schema:CreativeWork
205 sg:pub.10.1038/ajg.2008.138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028232194
206 https://doi.org/10.1038/ajg.2008.138
207 rdf:type schema:CreativeWork
208 sg:pub.10.1385/mo:18:3:209 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052059090
209 https://doi.org/10.1385/mo:18:3:209
210 rdf:type schema:CreativeWork
211 grid-institutes:None schema:alternateName Chief Surgical Officer and Associate Director for Clinical Science, Professor of Surgery, Rutgers Cancer Center Institute of New Jersey, 195 Little Albany Street, Room 2007, 08901, New Brunswick, NJ, USA
212 Chief of Medical Oncology and Professor of Medicine, St. Luke's Cancer Center, 18015, Bethlehem, PA, USA
213 schema:name Chief Surgical Officer and Associate Director for Clinical Science, Professor of Surgery, Rutgers Cancer Center Institute of New Jersey, 195 Little Albany Street, Room 2007, 08901, New Brunswick, NJ, USA
214 Chief of Medical Oncology and Professor of Medicine, St. Luke's Cancer Center, 18015, Bethlehem, PA, USA
215 rdf:type schema:Organization
216 grid-institutes:grid.213910.8 schema:alternateName Deputy Director, Professor of Medicine, Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Rd NW, NRB-E501, 20057, Washington, DC, USA
217 schema:name Deputy Director, Professor of Medicine, Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Rd NW, NRB-E501, 20057, Washington, DC, USA
218 rdf:type schema:Organization
219 grid-institutes:grid.257413.6 schema:alternateName Associate Director of Clinical Operations, Professor of Surgery, IU Simon Cancer Center, 550 N University Blvd, 46202, Indianapolis, IN, USA
220 schema:name Associate Director of Clinical Operations, Professor of Surgery, IU Simon Cancer Center, 550 N University Blvd, 46202, Indianapolis, IN, USA
221 rdf:type schema:Organization
222 grid-institutes:grid.437284.e schema:alternateName Senior Medical Director, Prometheus Laboratories Inc, 9410 Carroll Park Drive, 92121, San Diego, CA, USA
223 schema:name Senior Medical Director, Prometheus Laboratories Inc, 9410 Carroll Park Drive, 92121, San Diego, CA, USA
224 rdf:type schema:Organization
225 grid-institutes:grid.478063.e schema:alternateName Associate Professor of Medicine and Translational Science, University of Pittsburgh Cancer Institute, Suite 555, 5150 Centre Ave, 15232, Pittsburgh, PA, USA
226 schema:name Associate Professor of Medicine and Translational Science, University of Pittsburgh Cancer Institute, Suite 555, 5150 Centre Ave, 15232, Pittsburgh, PA, USA
227 rdf:type schema:Organization
228 grid-institutes:grid.478570.9 schema:alternateName Associate Director, Cancer Research Foundation, Chappaqua, NY, USA
229 schema:name Associate Director, Cancer Research Foundation, Chappaqua, NY, USA
230 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...